Medicines Discovery Catapult Ltd and its wholly-owned subsidiary, Medicines Discovery Catapult Services Commercial Ltd together being The Medicines Discovery Catapult (MDC) are part of a network of Catapults, established by Innovate UK to support UK innovation. Each Catapult specialises in a different area of technology, but all offer a space with the facilities and expertise to enable businesses and researchers to collaboratively solve key problems and develop new products and services – taking innovative ideas from concept to reality. Catapults are not-for-profit, independent organisations.
MDC is focused on reshaping the medicine discovery industry.
MDC recognises that it has a responsibility to take a robust approach to slavery and human trafficking. MDC is committed to preventing slavery and human trafficking in its corporate activities, and to ensure that its supply chains are free from slavery and human trafficking.
Organisational Structure:
The MDC main site office is based at Alderley Park in Macclesfield, Cheshire, England and employs 123 people. MDC employs a variety of roles including scientists, commercial, corporate compliance, management, administrative and other research professionals. The organisation has a permanent presence within the United Kingdom. Whilst it does not have any permanent presence within other countries, it does carry out overseas recruitment activity.
Supply Chains:
Our procurement activities take place within the United Kingdom and our contractors and suppliers are predominately UK, EU and US-based. We expect our supply chain to fully comply with the Modern Slavery Act 2015 and be transparent, accountable and auditable.
Our Policies and Processes:
MDC have implemented and maintain a Modern Slavery Policy which is accessible by all employees, as well as having suitable Anti-Bribery & Corruption and Whistleblowing Policies to ensure our business acts ethically.
The organisation’s procurement policies take reasonable practicable steps to ensure that all suppliers confirm their compliance with the Modern Slavery Act 2015. Those who declare that they do not comply will be excluded or disqualified from the procurement process. In addition, the MDC standard supplies/services contract requires a supplier to comply with the Modern Slavery Act 2015.
Further steps:
Following a review of the steps MDC has taken to ensure that there is no slavery or human trafficking in our supply chains we intend to take the following further steps to combat slavery and human trafficking:
- Provide training to MDC employees to ensure a suitable level of awareness of the risks of modern slavery and human trafficking in our business and supply
- Review how modern slavery is incorporated in our contract management
- Incorporate specific provisions into the MDC standard supplies/service contract which requires a supplier, and any other entities in its supply chains, to comply with all applicable anti-slavery and human trafficking laws, regulations and codes, and to not engage in any activity, practice or conduct which would constitute an offence under the Modern Slavery Act
This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes our slavery and human trafficking statement for the financial year ending [DATE].
It was approved by the Board on 19th May 2021.
Prof Chris Molloy, CEO/Director
Medicines Discovery Catapult Ltd and Medicines Discovery Catapult Services Commercial Ltd
Date: 19th May 2021
You can read our Modern Slavery policy here.